StreetAlpha.app
Home › Stocks › PTCT

Ptc Therapeutics, Inc. (PTCT)

Healthcare
$60.36
▼ −1.00%
LAST CLOSE · NOV 17

PTC Therapeutics develops and markets prescription drugs, including Sephience and Emflaza, for patients treated by doctors. It last closed at $60.36 on Nov 17, down 1.00% on the day. PTCT last reported earnings on Thu, Oct 29, 2026. The average 12-month price target from 7 analysts is $102.57 (+69.9% from the last close), with a high of $137.00 and a low of $77.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in PTCT, 0% of them bullish and 100% bearish. In the past 30 days there were 1 dark pool print totaling $553K, the largest $553K.

AI Auto Pilots
Is PTCT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.2B
−35.1% vs a year ago
Net income
−$106.0M
−114.1% vs a year ago
EPS (diluted)
−$1.33
−115.5% vs a year ago
Free cash flow
$2.1M
0.2% margin
Valuation
Market cap
$5.0B
83.5M shares
P/E
–
No P/E while losing money
Price to sales
4.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$508.9M
At Sep 30
Debt
$536.3M
At Sep 30
Shareholder equity
−$191.2M
Shares outstanding
83.5M
At Oct 27
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $538.6M$538.6MFY2021FY2022: $698.8M$698.8MFY2022FY2023: $937.8M$937.8MFY2023FY2024: $806.8M$806.8MFY2024FY2025: $1.7B$1.7BFY2025

From PTCT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Last report
Oct 29
2026 · After the close (AMC)
Reported EPS
$0.61
vs $0.17 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±11.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
6 Buy1 Hold0 Sell
Each firm's latest rating on PTCT in the past 90 days
Average 12-month target
$102.57
▲ 69.9% upside

Based on 7 analysts who set a price target on PTCT in the past 90 days. The average target is $102.57, with a high of $137.00 and a low of $77.00, compared with the last close of $60.36.

Low $77.00Avg $102.57High $137.00
Blue marker: last close $60.36
Highest target$137.00
Average target$102.57
Lowest target$77.00
Latest rating changes
CitigroupMaintained
Nov 2Buy$109
TD CowenTarget raised
Oct 30Buy$90 → $95
RBC CapitalTarget raised
Oct 30Hold$75 → $77
Wells FargoTarget raised
Oct 30Buy$109 → $112
UBSAssumed coverage
Oct 15Buy$90
DateFirmActionRatingPrice target
Nov 2CitigroupMaintainedBuy$109
Oct 30TD CowenTarget raisedBuy$90 → $95
Oct 30RBC CapitalTarget raisedHold$75 → $77
Oct 30Wells FargoTarget raisedBuy$109 → $112
Oct 15UBSAssumed coverageBuy$90
Loading…

Technical Analysis

PTCT · as of the Nov 17 close · updated after every close
Downtrend

The stock is 5% below its 20 day and 6% below its 50 day average. It is 16% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $60.07, and the nearest resistance the Pivot R1 at $61.26.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 4.1%/day
Key levels
$90.8752 week high+50.5%
$70.02200 day average+16.0%
$69.65100 day average+15.4%
$63.7850 day average+5.7%
$63.74Swing high (Oct 21)+5.6%
$63.4120 day average+5.1%
$61.26Pivot R1+1.5%
$60.36Last close
$60.07Pivot−0.5%
$59.17Pivot S1−2.0%
$59.16Swing low (Nov 2)−2.0%
$58.8052 week low−2.6%
Indicators
RSI (14)41.48Middle of its rangeNeutral
MACD-0.35Below its signal lineBearish
Stochastic23.1Middle of its rangeNeutral
ADX (14)13.4No clear trend
Williams %R-86.8Oversold below −80, overbought above −20Oversold
CCI (20)-121.4Oversold below −100, overbought above 100Oversold
Rate of change−11.4%Change over 10 sessionsBearish
ATR (14)$2.50Typical daily range, 4.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PTCT

What happened before

See how PTCT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PTCT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PTCT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Nov 3 – Nov 3
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$553K
Largest print
$553K
Loading…

PTCT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼177 buying vs 211 selling
  • ▼Held by funds -24.8 pts
  • ▼Funds holding -26
  • ▲Superinvestors: 3 added, 2 cut
  • ▲Put/call 0.04 to 0.01
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding360386−6.7%
In funds' top 1057−28.6%
Held by funds112.4%137.2%−24.8 pts
New / increased55 / 12275 / 142−18.4%
Reduced / sold out135 / 76113 / 45+33.5%
Put/call ratio0.010.04−84.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PTCT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTCT is in one of them and how their past PTCT trades turned out.

PTCT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PTCT in an article yet. Here's the latest on the wider market.

PTCT Congress Trades

All congress trades →
Trades, 12 months
4
Buys
2
50%
Sells
1
25%
People
1
Last filed Sep 22
Who traded PTCT · since 2026
Latest 4 filings
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded Mar 4, 2026Filed May 14, 2026
$50K – $100KTraded Feb 26, 2026Filed May 14, 2026
$50K – $100KTraded Jan 26, 2026Filed May 14, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchBuy$15K – $50KMar 4, 2026May 14, 202671 d
Donald J TrumpExecutive branchBuy$50K – $100KFeb 26, 2026May 14, 202677 d
Donald J TrumpExecutive branchOther$50K – $100KJan 26, 2026May 14, 2026108 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ptc Therapeutics

PTC Therapeutics is a pharmaceutical company based in Warren, New Jersey. It develops and markets prescription drugs, including Sephience and Emflaza, and its products are often for conditions that affect a small number of patients. Sales depend heavily on coverage and reimbursement from government programs such as Medicare and Medicaid and from private insurers, as well as on physician prescribing.

Headquarters
Warren, NJ
Founded
1998